Continuing Medical Education
Imedex, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Imedex, LLC designates this educational activity for a maximum 1.50 of AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Who Should Attend
This educational activity is specifically designed for hematologists, internists, oncologists, and other physicians, physicians-in-training, and other healthcare professionals (nurse practitioners, physician assistants, nurses, pharmacists) interested and/or involved in the care of patients with lymphoma and myeloma.
Objectives
After successful completion of this educational activity, attendees should be able to:
- Describe the limitations of, and acquired resistance to, rituximab in patients with B-cell lymphomas
- Implement the best available regimens for patients with relapsed/refractory B-cell lymphomas
- Evaluate efficacy, toxicity and safety of the next generation anti-CD20 therapies for patients with B-cell lymphomas
- Discuss current trials and remaining questions these and future trials must address for improving outcomes in patients with B-cell lymphomas
Myron S. Czuczman, MD
Roswell Park Cancer Institute
Buffalo, New York
Peter W.M. Johnson, MD,FRCP
Southampton General Hospitale
Southampton, United Kingdom
Brian K. Link, MD
Department of Internal Medicine
Holden comprehensive Cancer Center at the University of Iowa
Iowa City, Iowa
Saturday, October 18, 2008
12:00 PM
Welcome
12:05 PM
Understanding rituximab resistance
Myron S. Czuczman, MD
12:25 PM
Current options for relapsed/refractory B-cell lymphomas
Peter W.M. Johnson, MD, FRCP
12:45 PM
Next generation anti-CD20 therapies for overcoming resistance in patients with B-cell lymphomas
Brian K.Link, MD
1:05 pm
Clinical trials in 2008 and beyond: Remaining questions
John P. Leonard, MD
1:25 pm
Chair summary and take home points
1:30 pm
Adjourn
Moderator:
John P. Leonard, MD
Center for Lymphoma Myeloma
Weill Medical College of Cornell University
New York, New York
ORGANIZER
Imedex
11675 Rainwater Drive, Suite 600
Alpharetta, GA 30009, USA
Tel.: +1 (770) 751 7332
Fax: +1 (770) 751 7334
Email: meetings@imedex.com
Web: www.imedex.com

Imedex is a brand and assumed name used by Imedex, LLC (hereby referred to as Imedex). Imedex is solely responsible for this agenda’s content. Although Imedex attempts to ensure that the information in our program is accurate and timely, matters and opinions discussed and/or presented with respect to clinical matters are those of the discussion participants only, and not necessarily those of Imedex. Moreover, although Imedex attempts to identify and integrate the most qualified medical professionals in our program, TO THE FULLEST EXTENT PERMITTED BY LAW, IMEDEX EXPRESSLY DISCLAIM ALL WARRANTIES, EITHER EXPRESS OR IMPLIED, STATUTORY OR OTHERWISE, INCLUDING BUT NOT LIMITED TO THE IMPLIED WARRANTIES OF MERCHANTABILITY, NON-INFRINGEMENT OF THIRD PARTIES’ RIGHTS, AND FITNESS FOR A PARTICULAR PURPOSE, WITH RESPECT TO THE CONTENT PRESENTED. IMEDEX FURTHER MAKES NO REPRESENTATIONS OR WARRANTIES ABOUT THE ACCURACY, RELIABILITY, COMPLETENESS OR TIMELINESS OF THE CONTENT OR ANY MATERIAL PRESENTED.
In addition, the material presented and related discussions are not intended to be medical advice, and the presentation or discussion of such material is not intended to create and does not establish a physician-patient relationship. Medical advice of any nature should be sought from an individual’s own physician.
Neither Imedex nor any of its subsidiaries or affiliates is affiliated with or formally endorsed by a medical society.
©2008 Imedex®, LLC. All rights reserved.
Reproduction in whole or part is prohibited without prior written consent from Imedex and contributing faculty.
This meeting is made possible thanks to an unrestricted educational grant from
Several options are available to companies interested in supporting this Congress. For more information, please contact Imedex at +1(770) 751 7332, or by email at cme@imedex.com.